The results showed that the level of VEGF was significantly increased with PD, IL-6/sIL-6R + PD or IL-6/sIL-6R + PD + EZH2 overexpression treatment (Fig. 6A) and CKD patients (Fig. 6B). Here, EZH2 is linked to chronic kidney disease.